Immunovant (IMVT) Other Accumulated Expenses (2023 - 2026)

Immunovant (IMVT) has 4 years of Other Accumulated Expenses data on file, last reported at $175000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 35.9% year-over-year to $175000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $175000.0 (down 35.9% YoY) and the FY2026 annual result came in at $175000.0, down 35.9% from the prior year.
• Other Accumulated Expenses eased to $175000.0 in Q1 2026, from $273000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $350000.0 in Q1 2023 to a low of $15000.0 in Q1 2024.
• A 4-year average of $203250.0 and a median of $224000.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses plunged 95.71% — and 2025, when it surged 1720.0%.
• Tracing IMVT's Other Accumulated Expenses over 4 years: stood at $350000.0 in 2023, then sank by 95.71% to $15000.0 in 2024, then surged by 1720.0% to $273000.0 in 2025, then tumbled by 35.9% to $175000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $175000.0 (Q1 2026), $273000.0 (Q1 2025), and $15000.0 (Q1 2024), per Business Quant data.